[
    [
        {
            "time": "2021-11-15",
            "original_text": "Don’t Lose Sight of Biogen’s Depression Drug. How It Could Send the Stock Much Higher.",
            "features": {
                "keywords": [
                    "Biogen",
                    "depression drug",
                    "stock higher"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Don’t Lose Sight of Biogen’s Depression Drug. How It Could Send the Stock Much Higher.",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-16",
            "original_text": "Amid Variant Concern, US Government Stops Distribution Of Eli Lilly's Bamlanivimab In Three States",
            "features": {
                "keywords": [
                    "variant concern",
                    "US government",
                    "Eli Lilly",
                    "Bamlanivimab",
                    "distribution stop"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Amid Variant Concern, US Government Stops Distribution Of Eli Lilly's Bamlanivimab In Three States",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-16",
            "original_text": "Lilly says its monoclonal antibody is no longer being ordered in 3 states due to variant concerns",
            "features": {
                "keywords": [
                    "Lilly",
                    "monoclonal antibody",
                    "variant concerns",
                    "ordered"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly says its monoclonal antibody is no longer being ordered in 3 states due to variant concerns",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]